STOCK TITAN

Harrow (NASDAQ: HROW) furnishes March 2026 corporate investor presentation

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Harrow, Inc. filed a current report to furnish an updated corporate investor presentation under Regulation FD. The presentation, dated March 2026, is provided as Exhibit 99.1 and may be used by management in investor conferences and meetings.

The company specifies that this material is being furnished, not filed, so it is not subject to Section 18 liability of the Exchange Act and is only incorporated into other securities filings if expressly referenced.

Positive

  • None.

Negative

  • None.
false 0001360214 0001360214 2026-03-10 2026-03-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 10, 2026

 

HARROW, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-35814   45-0567010

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

1A Burton Hills Blvd., Suite 200    
Nashville, Tennessee   37215
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (615) 733-4730

 

  Not Applicable  
  (Former Name or Former Address, if Changed Since Last Report)  

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name on exchange on which registered
Common Stock, $0.001 par value per share   HROW   The Nasdaq Stock Market LLC

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Act of 1934: Emerging growth company

 

If any emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 7.01. Regulation FD Disclosure.

 

The Company is furnishing as Exhibit 99.1 to this Current Report on Form 8-K a corporate presentation that may be used by management in connection with investor conferences and meetings with investors.

 

The information in this Item 7.01 (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

Item 9.01. Financial Statements and Exhibits

 

(d)   Exhibits
     
99.1   Harrow Corporate Presentation dated March 2026
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  HARROW, INC.
     
Dated: March 10, 2026 By: /s/ Andrew R. Boll
  Name: Andrew R. Boll
  Title: President & Chief Financial Officer

 

 

 

 

Exhibit 99.1

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 

FAQ

What did Harrow (HROW) disclose in its latest 8-K filing?

Harrow furnished a corporate investor presentation as Exhibit 99.1 to a current report. Management may use this March 2026 presentation in investor conferences and meetings, providing an overview of the company for stakeholders seeking updated corporate information.

Is Harrow’s March 2026 corporate presentation considered filed with the SEC?

No. Harrow states the March 2026 corporate presentation is furnished, not filed, under the Exchange Act. This means it is not subject to Section 18 liability and is only incorporated into other filings if specifically referenced by the company.

Why did Harrow (HROW) submit Exhibit 99.1 with this 8-K?

Harrow submitted Exhibit 99.1 to provide a corporate presentation that management may use in investor conferences and meetings. Furnishing the presentation under Regulation FD helps ensure consistent access to the same information for all investors and market participants.

What is the date of Harrow’s investor presentation in Exhibit 99.1?

The investor presentation attached as Exhibit 99.1 is dated March 2026. This date indicates when the materials were prepared and helps investors understand the timing and potential relevance of the corporate information being shared in meetings and conferences.

Who signed Harrow’s 8-K furnishing the March 2026 presentation?

The 8-K was signed on behalf of Harrow, Inc. by Andrew R. Boll, the company’s President and Chief Financial Officer. His signature confirms the company’s authorization of the filing and the furnished corporate presentation attached as Exhibit 99.1.

Filing Exhibits & Attachments

24 documents
Harrow Health Inc

NASDAQ:HROW

View HROW Stock Overview

HROW Rankings

HROW Latest News

HROW Latest SEC Filings

HROW Stock Data

1.34B
31.07M
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
NASHVILLE